+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Vasculitis Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035

  • PDF Icon

    Report

  • May 2025
  • Region: Global
  • BIS Research
  • ID: 6089547
10% Free customization
10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

Vasculitis is a rare but severe condition that results in inflammation of blood vessels, leading to a wide range of symptoms that can disrupt normal blood flow and damage affected organs. The variability in its presentation, from mild cases to severe manifestations, necessitates the development of targeted therapies. The growing focus on biologic treatments, such as monoclonal antibodies and advanced immunomodulators, will continue to play a key role in driving the global vasculitis market forward during the forecast period.

Technological advancements in diagnostics, as well as a growing understanding of the pathophysiology of vasculitis, are also expected to contribute significantly to market expansion. Personalized medicine and the integration of digital health solutions in treatment management are poised to revolutionize the therapeutic landscape for vasculitis patients.

North America is projected to remain the dominant region in the global vasculitis market. This is primarily due to the region’s advanced healthcare infrastructure, higher levels of patient awareness, and robust government funding aimed at fostering research into autoimmune diseases like vasculitis.

Demand - Drivers and Limitations


The global vasculitis market is witnessing rising demand due to several key drivers:

  • The rise in vasculitis cases is driven by an aging population, lifestyle factors, and improved awareness and diagnosis
  • Biologics and immunomodulators are revolutionizing vasculitis treatment with more targeted and effective therapies
  • Enhanced imaging, biomarkers, and genetic tests are enabling earlier and more accurate vasculitis diagnosis.

Limitations:

  • High costs of biologic therapies restrict access for some patients, particularly in low-income regions
  • There is an unmet need for effective treatments for specific rare and refractory forms of vasculitis

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The global vasculitis market is witnessing a surge in product innovations, particularly in the field of biologics and personalized medicine. This report provides valuable insights into the development of new treatment strategies, helping companies identify new product opportunities, particularly in biologic therapy and patient management solutions.

Competitive Strategy: Companies aiming to secure or enhance their market share in the global vasculitis market should focus on improving the efficacy and safety profiles of existing therapies, and exploring new biologic treatment combinations to offer personalized care solutions. Companies can also strengthen their position through strategic partnerships, collaborations with research institutions, and investments in early-stage diagnostics.

This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.

Table of Contents

Executive SummaryMarket/Product DefinitionInclusion and Exclusion
1. Global Vasculitis Market: Industry Outlook
1.1 Market Overview and Ecosystem
1.2 Epidemiological Analysis of Vasculitis
1.2.1 By Region
1.3 Market Trends
1.4 Clinical Trials Analysis
1.4.1 By Phase
1.5 Regulatory Landscape Analysis
1.5.1 Legal Requirement and Framework in U.S.
1.5.2 Legal Requirement and Framework in E.U.
1.5.3 Legal Requirement and Framework in Asia-Pacific
1.6 Market Dynamics
1.6.1 Impact Analysis
1.6.2 Market Drivers
1.6.3 Market Restraints
1.6.4 Market Opportunities
2. Global Vasculitis Market, by Region, $Million, 2023-2035
2.1 North America
2.1.1 Key Findings
2.1.2 Market Dynamics
2.1.3 Market Sizing and Forecast
2.1.3.1 North America Vasculitis Market (by Country)
2.1.3.1.1 U.S.
2.1.3.1.2 Canada
2.2 Europe
2.2.1 Key Findings
2.2.2 Market Dynamics
2.2.3 Market Sizing and Forecast
2.2.3.1 Europe Vasculitis Market (by Country)
2.2.3.1.1 Germany
2.2.3.1.2 France
2.2.3.1.3 Italy
2.2.3.1.4 U.K.
2.3 Asia-Pacific
2.3.1 Key Findings
2.3.2 Market Dynamics
2.3.3 Market Sizing and Forecast
2.3.3.1 Asia-Pacific Vasculitis Market (by Country)
2.3.3.1.1 Japan
3. Global Vasculitis Market: Competitive Benchmarking and Company Profiles
3.1 Competitive Landscape
3.1.1 Key Strategies and Developments
3.1.1.1 Funding Activities
3.1.1.2 Mergers and Acquisitions
3.1.1.3 Regulatory Approvals
3.1.1.4 Partnerships, Collaborations and Business Expansions
3.1.2 Key Developments Analysis
3.2 Company Profiles
3.2.1 GlaxoSmithKline
3.2.1.1 Company Overview
3.2.1.2 Product Portfolio
3.2.1.3 Target Customers/End Users
3.2.1.4 Key Personnels
3.2.1.5 Analyst View
3.2.2 Mitsubishi Tanabe Pharma Corporation
3.2.2.1 Company Overview
3.2.2.2 Product Portfolio
3.2.2.3 Target Customers / End Users
3.2.2.4 Key Personnels
3.2.2.5 Analyst View
3.2.3 Novartis AG
3.2.3.1 Company Overview
3.2.3.2 Product Portfolio
3.2.3.3 Target Customers / End Users
3.2.3.4 Key Personnels
3.2.3.5 Analyst View
3.2.4 Amgen
3.2.4.1 Company Overview
3.2.4.2 Product Portfolio
3.2.4.3 Target Customers / End Users
3.2.4.4 Key Personnels
3.2.4.5 Analyst View
4. Research Methodology
List of Figures
Figure: Global Vasculitis Market Coverage
Figure: Global Vasculitis Market, Key Trends, Impact Analysis
Figure: Global Vasculitis Market, Competitive Landscape
List of Tables
Table: Global Vasculitis Market, Dynamics, Impact Analysis
Table: Global Vasculitis Market, Regulatory Landscape
Table: Global Vasculitis Market, (by Region), $Million, 2023-2035

Companies Mentioned

  • GlaxoSmithKline
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Amgen